Corvert

(Ibutilide)

PreclinicalSmall molecule

Pfizer

Corvert is one of 24 small molecule programs targeting Atrial Fibrillation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Atrial FibrillationActive, not recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 2

Imbruvica

PPharmacyclics LLC.

Preclinical

1 3

Anticoagulants

Sanofi

Preclinical

2 4

Direct Anticoagulant

Bayer

Preclinical

1 5

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 6

Statin

Bristol-Myers Squibb

Preclinical

1 7

Warfarin Sodium

Boehringer Ingelheim

Preclinical

3 8

Magnesium SO4

HHospital de Base

Preclinical

2 9

Medication

NNYU Langone Health

Preclinical

1 10

Anticoagulation

HHospital Álvaro Cunqueiro

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

GAN1 trial

ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization

Terminated·VVivek Reddy·N/A·NCT03370536·1 enrolled

Drug1 trial

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

Completed·IIndiana University·Phase 4·NCT04675788·73 enrolled

Torsades de Pointes1 trial

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

Completed·IIndiana University·Phase 4·NCT02513940·14 enrolled

Progesterone1 trial

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

Completed·IIndiana University·Phase 2·NCT01929083·19 enrolled

Women1 trial

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Completed·IIndiana University·Phase 4·NCT03834883·27 enrolled

1 more indication

Atrial Fibrillation1 trial

Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation

Completed·VVivek Reddy·N/A·NCT01014741·200 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 28, 1995

CORVERT

NDA NDA020491

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Ibutilide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ibutilide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ibutilide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020491). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

Corvert

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

GAN1 trial

Drug1 trial

Torsades de Pointes1 trial

Progesterone1 trial

Women1 trial

Atrial Fibrillation1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News